In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer.  

Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice. 

Guests:
Dr. Julia Rotow 
Clinical Director and Research Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute 

 
Dr. Roy Herbst 
Director, Dartmouth Cancer Center 
Professor, Geisel School of Medicine at Dartmouth 

Dr. Daniel Shao-Weng Tan 
Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore 
Professor, Duke-NUS Medical School 
Senior Clinician-Scientist, Genome Institute of Singapore

LCC in Portuguese: WCLC 2026 Highlights

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by Current sponsors: 
•	AbbVie 
•	AstraZeneca
•	Gilead
•	J&J
•	Summit